lidocaine, prilocaine

Cream

Composition
Active constituents
1 g of Emla Cream contains lidocaine 25 mg, prilocaine 25 mg.
For excipients see List of excipients.

Pharmaceutical form

Cream.
Emla is an oil/water emulsion in which the oil phase consists of a eutectic mixture of lidocaine and prilocaine in the ratio 1:1.

Therapeutic indications

Surface anaesthesia of the skin in connection with needle insertion and for superficial surgical procedures.
Surface anaesthesia of leg ulcers prior to cleaning and superficial surgical procedures, for example removal of fibrin, pus and necroses.
Surface anaesthesia of the genital mucosa.

Posology and method of administration

Adults
Intact skin

<table>
<thead>
<tr>
<th>Dose and administration</th>
<th>Application time</th>
</tr>
</thead>
<tbody>
<tr>
<td>for needle insertion e.g. insertion of intravenous lines, taking blood samples</td>
<td>½ tube (approx. 2 g) per 10 cm². A thick layer of cream is applied to the skin and covered with an occlusive dressing</td>
</tr>
<tr>
<td>for minor superficial surgical procedures, e.g. curettage of the lesions caused by mollusca contagiosum</td>
<td>1.5-2 g per 10 cm². A thick layer of cream is applied to the skin and covered with an occlusive dressing</td>
</tr>
<tr>
<td>for superficial surgical procedures on larger areas, e.g. split skin grafting</td>
<td>1.5-2 g per 10 cm². A thick layer of cream is applied to the skin and covered with an occlusive dressing</td>
</tr>
</tbody>
</table>

Leg ulcers
For cleaning of leg ulcers: approx. 1-2 g per 10 cm².
The cream is applied in a thick layer to the surface of the ulcer, but not more than 10 g per treatment procedure. Cover the surface of the ulcer with an occlusive dressing. An opened tube is intended for a single use, and any remaining cream must therefore be discarded after each treatment procedure.
Application time: at least 30 minutes.
For leg ulcers with tissue that is particularly difficult to penetrate the application time may be extended to 60 minutes. Cleaning of the ulcer should begin within 10 minutes after the cream has been removed.
Emla has been used for up to 15 treatment procedures over a period of 1-2 months without a decline in effect or an increase in the number of local reactions.

Genital use

Skin
Use prior to injection of local anaesthetics:

Men
1 g per 10 cm². A thick layer of cream is applied to the skin under an occlusive dressing.
Application time: 15 minutes.

Women
1-2 g per 10 cm². A thick layer of cream is applied to the skin under an occlusive dressing.
Application time: 60 minutes.

Genital mucosa
For removal of condyloma or prior to injection of local anaesthetics: approx. 5-10 g, depending on the area to be treated. The whole surface, including the mucosal folds, must be covered. Occlusion is not necessary.
Application time: 5-10 minutes. The surgery must be begun immediately after removal of the cream.

Children
For needle insertion, curettage of the lesions caused by mollusca contagiosum and other minor surgical procedures:
1 g per 10 cm².
A thick layer of cream is applied to the skin and covered with an occlusive dressing. The dose should not exceed 1 gram per 10 cm² and must be adjusted according to the application area:

<table>
<thead>
<tr>
<th>Age</th>
<th>Application area</th>
<th>Application time</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-3 months</td>
<td>maximum 10 cm²</td>
<td>1 hour (note: not longer)</td>
</tr>
<tr>
<td></td>
<td>(total of 1 g)</td>
<td></td>
</tr>
<tr>
<td>3-12 months</td>
<td>maximum 20 cm²</td>
<td>1 hour</td>
</tr>
<tr>
<td></td>
<td>(total of 2 g)</td>
<td></td>
</tr>
<tr>
<td>1-6 years</td>
<td>maximum 100 cm²</td>
<td>1 hour max 5 hours</td>
</tr>
<tr>
<td></td>
<td>(total of 10 g)</td>
<td></td>
</tr>
<tr>
<td>6-12 years</td>
<td>maximum 200 cm²</td>
<td>1 hour max 5 hours</td>
</tr>
<tr>
<td></td>
<td>(total of 20 g)</td>
<td></td>
</tr>
</tbody>
</table>

A longer application time decreases the anaesthesia. Children with atopic dermatitis: reduce application time to 30 minutes.

1 g of EMLA cream administered from the 30 g aluminium tube corresponds to a length of extruded cream of approximately 3.5 cm.

**Contraindications**

Hypersensitivity to local anaesthetics of the amide type. Emla must not be used in premature infants (born before week 37 of pregnancy).

**Special warnings and precautions for use**

Patients with glucose-6-phosphate dehydrogenase deficiency or congenital or idiopathic methaemoglobinemia are more susceptible to drug induced methaemoglobinemia.

Studies have been unable to demonstrate the efficacy of Emla for heel lancing in neonates.

Caution when using near the eyes, as Emla may cause eye irritation. Also the loss of protective reflexes may allow corneal irritation and potential abrasion. If eye contact occurs, immediately rinse the eye in water or sodium chloride solution and protect until sensation returns.

Caution when using on areas on skin with atopic dermatitis; the application time should be reduced (15-30 minutes).

In children under 3 months, safety and efficacy have only been studied with application of a single dose. In these children, a transient increase in methaemoglobin levels is often seen for up to 13 hours after Emla has been applied. However, the increases that have been observed are probably of no clinical significance.

Patients treated with anti-arrhythmic drugs class III (eg, amiodarone) should be under close surveillance and ECG monitoring considered, since cardiac effects may be additive.

Emla should not be used on damaged tympanic membrane or in other situations where penetration into the middle ear may occur.

Emla should not be applied to open wounds.

Emla should not be used on the genital mucosa in children on account of incomplete data of absorption.

Lidocaine and prilocaine have bacteriocidal and antiviral properties in concentrations above 0.5-2%. For this reason the results of intracutaneous injections of live vaccines (e.g. BCG) should be monitored.

Until further clinical experience is available, Emla should not be used for children aged 0-12 months during concomitant treatment with methaemoglobin-inducing drugs (see also Overdose).

**Interactions**

Emla can potentiate the formation of methaemoglobin in patients who are being treated with certain methaemoglobin-inducing preparations (e.g. sulpha preparations).

With high doses of Emla, the risk of additive systemic effects should be taken into account in patients who are given local anaesthetics or preparations that are structurally similar to local anaesthetics, e.g. tocainide.

Specific interaction studies with lidocaine/prilocaine and anti-arrhythmic drugs class III (eg, amiodarone) have not been performed, but caution is advised.

**Pregnancy and lactation**

**Pregnancy**

Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. In both animal and humans, lidocaine and prilocaine cross the placental barrier and may be absorbed by the foetal tissue. It is reasonable to assume that lidocaine and prilocaine have been used in a large number of pregnant women.
and women of childbearing potential. No specific disturbances to the reproductive process have so far been reported, e.g. an increased incidence of malformations or other directly or indirectly harmful effects on the foetus. However, caution should be exercised when used in pregnant women.

Lactation
Lidocaine and prilocaine pass into the breast milk, but the risk of an effect on the child appears unlikely with therapeutic doses.

Effects on ability to drive and use machines
Reaction capacity is not affected by treatment with Emla.

Undesirable effects
Adverse events with local anaesthetics in the actual sense of the term occur in fewer than 1/1000 patients treated.

<table>
<thead>
<tr>
<th>Common (&gt;1/100)</th>
<th>Less common</th>
<th>Rare (&lt;1/1000)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin: transient local reactions at the application site, such as paleness, redness, oedema.</td>
<td>Skin: Initially a slight burning sensation, itching (at the application site)</td>
<td>General: Allergic reactions, in the most severe cases anaphylactic shock. Methaemoglobinemia in children.</td>
</tr>
</tbody>
</table>

Rare cases of discrete reactions at the application site, such as purpura or petechia, have been reported, especially following longer application times in children with atopic dermatitis or molluscus. Corneal irritation after accidental eye exposure.

Overdose
Systemic toxicity is very unlikely with normal use of Emla. In the event of toxicity, the symptoms are expected to be similar to those seen after local anaesthesia treatment, i.e. excitatory CNS symptoms and in severe cases CNS depression and myocardial depression.

Rare cases of clinically significant methaemoglobinemia in children have been reported. Prilocaine in high doses can increase the methaemoglobin level.

Topical administration of 125 mg prilocaine for 5 hours caused moderate methaemoglobinemia in a 3-months-old child. Topical administration of 8.6-17.2 mg/kg lidocaine caused very serious intoxication in infants.

Severe neurological symptoms (convulsions, CNS depression) require symptomatic treatment such as assisted ventilation and anticonvulsant therapy.

In the event of methaemoglobinemia methylthionium is the antidote. On account of a slow systemic absorption, a patient with symptoms of toxicity should be kept under observation for several hours following any treatment of these symptoms.

Pharmacodynamic properties
ATC code: N01B B20
Emla cream contains lidocaine and prilocaine, which are local anaesthetics of the amide type. On penetration into the epidermis and dermis, these substances produce dermal anaesthesia.

The degree of anaesthesia depends on application time and dose.

Intact skin
With an application time of 1-2 hours the effect lasts for approximately two hours after the occlusive dressing has been removed.

In clinical studies of Emla on intact skin, no differences in safety or efficacy (including anaesthetic onset time) were observed between geriatric patients (aged 65-96 years) and younger patients.

The superficial vascular bed is affected by Emla, and this can cause transient paleness or redness. These reactions appear to occur more rapidly in atopic dermatitis, after only 30-60 minutes, indicating more rapid absorption through the skin (see also Special warnings and precautions for use).

A study in healthy volunteers with intact skin shows that in 90% the anaesthesia is sufficient for use of biopsy punch (4 mm in diameter) to an insertion depth of 2 mm, following 60 minutes application time and to a depth of 3 mm following 120 minutes application time.

The effectiveness of Emla is independent of the colour of the skin/pigmentation of the skin (skin types I-IV).

The use of Emla prior to measles-mumps-rubella or intramuscular diphtheria-pertussis-tetanus-inactivated poliovirus-Haemophilus influenzae b or Hepatitis B vaccines does not affect mean antibody titres, rate of seroconversion, or the proportion of patients
achieving protective or positive antibody titres post immunization, as compared to placebo treated patients.

Genital mucosa
The time to onset of the necessary anaesthesia is shorter, as absorption is more rapid than with application to intact skin.
Following 5-10 minutes application of Emla to the genital mucosa in women, the anaesthetic effect against argon laser induced pain lasted for 15-20 minutes (with an interindividual variation from 5-45 minutes).

Leg ulcers
No negative effect on ulcer healing or bacterial flora has been observed. When cleaning leg ulcers Emla has analgesic effect for up to 4 hours after application.

Pharmacokinetic properties
The systemic absorption of Emla depends on the amount of cream, the application time, the thickness of the skin (which varies on different surfaces of the body) and the skin’s condition otherwise.

Intact skin
After application of 60 g Emla cream per 400 cm² (1.5 g per 10 cm²) for three hours to intact skin (the thigh) in adults, systemic absorption was measured as 3% for lidocaine and 5% for prilocaine. Absorption takes place slowly. With the above mentioned dose, peak plasma concentrations for lidocaine (mean 0.12 µg/ml) and prilocaine (mean 0.07 µg/ml) were reached within approximately 4 hours after application. Only at levels of 5-10 µg/ml are there risks of toxic symptoms.
Plasma levels of lidocaine and prilocaine in both geriatric and non-geriatric patients following application of Emla to intact skin are very low and well below potentially toxic levels.

Leg ulcers
After application to leg ulcers of 5-10 g Emla for 30 minutes peak plasma levels of lidocaine and prilocaine were reached after approximately 1-2.5 hours (for lidocaine within the range 0.05-0.84 µg/ml and for prilocaine 0.02-0.08 µg/ml).

Following repeated application of Emla to leg ulcers there was no apparent accumulation in plasma of lidocaine, prilocaine or their metabolites. 2-10 g Emla was applied for 30-60 minutes to a maximal surface of 62 cm², in total 15 times during a period of one month, 3-7 sessions a week.

Genital mucosa
After application of 10 g Emla cream to vaginal mucosa for 10 minutes, peak plasma concentrations were measured after approximately 35 minutes (mean values: lidocaine 0.18 µg/ml, prilocaine 0.15 µg/ml).

List of excipients
Carbomer, polyoxyethylene hydrated castor oil. Sodium hydroxide to pH 8.7-9.7, water.

Shelf life
Please refer to expiry date on the outer carton.

Special precautions for storage
Do not store above 30°C. Do not freeze.

Pack size
Please refer to outer carton for pack size.

Instructions for use and handling
Use the tube cap in order to perforate the membrane covering the tip of the tube.

Date of revision of the text
February 2006